Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Gynecology

  Free Subscription


Articles published in Int J Oncol

Retrieve available abstracts of 32 articles:
HTML format



Single Articles


    December 2024
  1. LIU Y, Xiao H, Zeng H, Xiang Y, et al
    Beyond tumor?associated macrophages involved in spheroid formation and dissemination: Novel insights for ovarian cancer therapy (Review).
    Int J Oncol. 2024;65:117.
    PubMed     Abstract available


    November 2024
  2. ZHU Y, Yang W, Wang X, Chen M, et al
    AUP1 transcriptionally activated by KDM5B reprograms lipid metabolism to promote the malignant progression of cervical cancer.
    Int J Oncol. 2024;65:107.
    PubMed     Abstract available


  3. TAN H, He Q, Gong G, Wang Y, et al
    [Corrigendum] miR-382 inhibits migration and invasion by targeting ROR1 through regulating EMT in ovarian cancer.
    Int J Oncol. 2024;65:110.
    PubMed     Abstract available


    October 2024
  4. SUN J, Chu H, Ji J, Huo G, et al
    [Retracted] Long non?coding RNA HOTAIR modulates HLA?G expression by absorbing miR?148a in human cervical cancer.
    Int J Oncol. 2024;65:97.
    PubMed     Abstract available


    August 2024
  5. XU S, Zhu C, Xu Q, An Z, et al
    ARID1A restrains EMT and stemness of ovarian cancer cells through the Hippo pathway.
    Int J Oncol. 2024;65:76.
    PubMed     Abstract available


    June 2024
  6. FU M, Deng F, Chen J, Fu L, et al
    Current data and future perspectives on DNA methylation in ovarian cancer (Review).
    Int J Oncol. 2024;64:62.
    PubMed     Abstract available


    March 2024
  7. GRUNT TW, Wagner R, Ries A, Berghoff AS, et al
    Targeting endogenous fatty acid synthesis stimulates the migration of ovarian cancer cells to adipocytes and promotes the transport of fatty acids from adipocytes to cancer cells.
    Int J Oncol. 2024;64:24.
    PubMed     Abstract available


  8. GENG D, Zhou Y, Wang M
    Advances in the role of GPX3 in ovarian cancer (Review).
    Int J Oncol. 2024;64:31.
    PubMed     Abstract available


  9. INOUE F, Sone K, Kumegawa K, Hachijo R, et al
    Inhibition of protein arginine methyltransferase 6 activates interferon signaling and induces the apoptosis of endometrial cancer cells via histone modification.
    Int J Oncol. 2024;64:32.
    PubMed     Abstract available


    January 2024
  10. LIU Y, Yang Y, Wang X, Yin S, et al
    Function of microRNA?124 in the pathogenesis of cancer (Review).
    Int J Oncol. 2024;64:6.
    PubMed     Abstract available


    December 2023
  11. QI Y, Ma N, Zhang J
    Tripartite motif containing 33 demonstrated anticancer effect by degrading c?Myc: Limitation of glutamine metabolism and proliferation in endometrial carcinoma cells.
    Int J Oncol. 2023;63:133.
    PubMed     Abstract available


  12. LIANG T, Lu T, Jia W, Li R, et al
    Knockdown of lncRNA MALAT1 induces pyroptosis by regulating the miR?124/SIRT1 axis in cervical cancer cells.
    Int J Oncol. 2023;63:138.
    PubMed     Abstract available


    November 2023
  13. DENG F, Fu M, Zhao C, Lei J, et al
    Calcium signals and potential therapy targets in ovarian cancer (Review).
    Int J Oncol. 2023;63:125.
    PubMed     Abstract available


    October 2023
  14. YUAN J, Guan W, Li X, Wang F, et al
    RBM15‑mediating MDR1 mRNA m(6)A methylation regulated by the TGF‑beta signaling pathway in paclitaxel‑resistant ovarian cancer.
    Int J Oncol. 2023;63:112.
    PubMed     Abstract available


    September 2023
  15. O'DONNELL J, Zhao Z, Buckingham L, Hao T, et al
    Ipatasertib exhibits anti‑tumorigenic effects and enhances sensitivity to paclitaxel in endometrial cancer in vitro and in vivo.
    Int J Oncol. 2023;63:103.
    PubMed     Abstract available


    August 2023
  16. ZHAI L, Yang X, Dong J, Qian L, et al
    O‑GlcNAcylation mediates endometrial cancer progression by regulating the Hippo‑YAP pathway.
    Int J Oncol. 2023;63:90.
    PubMed     Abstract available


    May 2023
  17. CHEN Q, Shen S, Lv N, Tong J, et al
    Role of microRNAs in glycolysis in gynecological tumors (Review).
    Int J Oncol. 2023;62:63.
    PubMed     Abstract available


    December 2022
  18. KARIN-KUJUNDZIC V, Covarrubias-Pinto A, Skrtic A, Vranic S, et al
    New insight into the role of PTCH1 protein in serous ovarian carcinomas.
    Int J Oncol. 2022;61.
    PubMed     Abstract available


  19. SHEN S, Guo J, Lv N, Chen Q, et al
    RNA m6A methylation regulators in endometrial cancer (Review).
    Int J Oncol. 2022;61.
    PubMed     Abstract available


    November 2022
  20. ENDO Y, Sugimoto K, Kobayashi M, Kobayashi Y, et al
    Claudin9 is a novel prognostic biomarker for endometrial cancer.
    Int J Oncol. 2022;61.
    PubMed     Abstract available


    October 2022
  21. WANG Y, Han A, Chen E, Singh RK, et al
    [Corrigendum] The cranberry flavonoids PAC DP9 and quercetin aglycone induce cytotoxicity and cell cycle arrest and increase cisplatin sensitivity in ovarian cancer cells.
    Int J Oncol. 2022;61.
    PubMed     Abstract available


  22. LI R, Wang Y, Xu Y, He X, et al
    [Retracted] Silencing the long noncoding RNA, TINCR, a molecular sponge of miR335, inhibits the malignant phenotype of epithelial ovarian cancer via FGF2 suppression.
    Int J Oncol. 2022;61.
    PubMed     Abstract available


  23. BJERSAND K, Blom K, Poromaa IS, Stalberg K, et al
    Ex vivo assessment of cancer drug sensitivity in epithelial ovarian cancer and its association with histopathological type, treatment history and clinical outcome.
    Int J Oncol. 2022;61.
    PubMed     Abstract available


  24. KIM SH, Baek KH
    Ovarian tumor deubiquitinase 6A regulates cell proliferation via deubiquitination of nucleolin and caspase7.
    Int J Oncol. 2022;61.
    PubMed     Abstract available


    July 2022
  25. XU L, Li J, Tursun M, Hai Y, et al
    Receptor for activated C kinase 1 promotes cervical cancer lymph node metastasis via the glycolysisdependent AKT/mTOR signaling.
    Int J Oncol. 2022;61.
    PubMed     Abstract available


  26. FEDIER A, Maggi N, Tozzi A, Disler M, et al
    Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines.
    Int J Oncol. 2022;61.
    PubMed     Abstract available


    May 2022
  27. ZHANG R, Roque DM, Reader J, Lin J, et al
    Combined inhibition of IL6 and IL8 pathways suppresses ovarian cancer cell viability and migration and tumor growth.
    Int J Oncol. 2022;60.
    PubMed     Abstract available


  28. LAVORO A, Scalisi A, Candido S, Zanghi GN, et al
    Identification of the most common BRCA alterations through analysis of germline mutation databases: Is droplet digital PCR an additional strategy for the assessment of such alterations in breast and ovarian cancer families?
    Int J Oncol. 2022;60.
    PubMed     Abstract available


    March 2022
  29. LI L, Yu J, Duan Z, Dang HX, et al
    [Corrigendum] The effect of NFATc1 on vascular generation and the possible underlying mechanism in epithelial ovarian carcinoma.
    Int J Oncol. 2022;60.
    PubMed     Abstract available


  30. SINGH T, Neal A, Dibernardo G, Raheseparian N, et al
    Efficacy of birinapant in combination with carboplatin in targeting platinumresistant epithelial ovarian cancers.
    Int J Oncol. 2022;60.
    PubMed     Abstract available


    January 2022
  31. FAN LX, Tao L, Lai YC, Cai SY, et al
    Cx32 promotes autophagy and produces resistance to SNinduced apoptosis via activation of AMPK signalling in cervical cancer.
    Int J Oncol. 2022;60.
    PubMed     Abstract available


    July 2021
  32. FALZONE L, Scandurra G, Lombardo V, Gattuso G, et al
    A multidisciplinary approach remains the best strategy to improve and strengthen the management of ovarian cancer (Review).
    Int J Oncol. 2021;59.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Gynecology is free of charge.